-
1.发明授权Methods using recombinant anti-epidermal growth factor receptor antibody compositions 有权使用重组抗表皮生长因子受体抗体组合物的方法公开(公告)号：US08663640B2
公开(公告)日：2014-03-04
申请号：US13061417
申请日：2009-08-27
IPC分类号： A61K39/395 , C07K16/30
CPC分类号： C07K16/2863 , A61K2039/507 , C07K14/71 , C07K2317/24 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumors following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumors. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.
摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供了对人EGFR具有两种不同的非重叠结合特异性的抗体组合物的用途。 抗体组合物在用其他抗EGFR抗体治疗后，无论癌症是否在先前治疗期间或之后显示进展，都在治疗癌症中。 在本发明的抗体组合物一线治疗后，抗体组合物也可用于重复治疗复发性肿瘤，因为该组合物不导致抗性肿瘤的选择。 进一步的治疗用途是使用本发明的抗体组合物治疗对已知抗EGFR抗体具有抗性的癌症。
-
公开(公告)号：US09217039B2
公开(公告)日：2015-12-22
申请号：US13882807
申请日：2011-10-31
IPC分类号： A61K39/395 , C07K16/40 , C07K16/28 , C07K16/32 , A61K39/00
CPC分类号： C07K16/40 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/2863 , C07K16/32 , C07K2317/24 , C07K2317/73 , C07K2317/76
摘要： The present invention relates to novel therapeutic recombinant antibodies directed against HER3 (ErbB3), as well as compositions comprising mixtures of at least two of said recombinant anti-HER3 antibodies, and use of the antibodies and antibody compositions for treatment of cancer.
摘要翻译： 本发明涉及针对HER3（ErbB3）的新型治疗性重组抗体，以及包含至少两种所述重组抗HER3抗体的混合物的组合物，以及抗体和抗体组合物用于治疗癌症的用途。
-
公开(公告)号：US20130287684A1
公开(公告)日：2013-10-31
申请号：US13882807
申请日：2011-10-31
IPC分类号： C07K16/40 , A61K39/395
CPC分类号： C07K16/40 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/2863 , C07K16/32 , C07K2317/24 , C07K2317/73 , C07K2317/76
摘要： The present invention relates to novel therapeutic recombinant antibodies directed against HER3 (ErbB3), as well as compositions comprising mixtures of at least two of said recombinant anti-HER3 antibodies, and use of the antibodies and antibody compositions for treatment of cancer.
摘要翻译： 本发明涉及针对HER3（ErbB3）的新型治疗性重组抗体，以及包含至少两种所述重组抗HER3抗体的混合物的组合物，以及抗体和抗体组合物用于治疗癌症的用途。
-
公开(公告)号：US20120107234A1
公开(公告)日：2012-05-03
申请号：US13286471
申请日：2011-11-01
IPC分类号： A61K39/395 , A61K51/10 , C12N15/13 , C12N1/21 , C12N5/10 , C12P21/00 , C12N1/19 , C12N1/15 , A61P35/00 , C12N15/63
CPC分类号： C07K16/32 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/48546 , A61K47/48569 , A61K47/6845 , A61K47/6851 , A61K2039/507 , A61N5/10 , C07K16/2863 , C07K16/30 , C07K16/3015 , C07K16/303 , C07K16/3053 , C07K16/3069 , C07K16/40 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.
摘要翻译： 本发明涉及改善EGFR / ErbB / HER家族内受体的治疗剂，其更广泛地干扰HER家族的多个成员（pan-HER抑制）。 更具体地，本发明涉及抗体组合物用于人类癌症治疗的用途。 体外研究已经显示靶向多种HER家族受体的本发明的抗体组合物优于靶向仅一种HER家族受体的抗体组合物。
-
公开(公告)号：US09155802B2
公开(公告)日：2015-10-13
申请号：US13286471
申请日：2011-11-01
IPC分类号： A61K39/395 , A61K47/48 , C07K16/28 , C07K16/32 , A61K39/00
CPC分类号： C07K16/32 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/48546 , A61K47/48569 , A61K47/6845 , A61K47/6851 , A61K2039/507 , A61N5/10 , C07K16/2863 , C07K16/30 , C07K16/3015 , C07K16/303 , C07K16/3053 , C07K16/3069 , C07K16/40 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.
摘要翻译： 本发明涉及改善EGFR / ErbB / HER家族内受体的治疗剂，其更广泛地干扰HER家族的多个成员（pan-HER抑制）。 更具体地，本发明涉及抗体组合物用于人类癌症治疗的用途。 体外研究已经显示靶向多种HER家族受体的本发明的抗体组合物优于靶向仅一种HER家族受体的抗体组合物。
-
公开(公告)号：US20110229463A1
公开(公告)日：2011-09-22
申请号：US13061417
申请日：2009-08-27
IPC分类号： A61K39/395 , C07K16/32 , C12N5/09 , A61P35/00
CPC分类号： C07K16/2863 , A61K2039/507 , C07K14/71 , C07K2317/24 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumours following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumours. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.
摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供了对人EGFR具有两种不同的非重叠结合特异性的抗体组合物的用途。 抗体组合物在用其他抗EGFR抗体治疗后，无论癌症是否在先前治疗期间或之后显示进展，都在治疗癌症中。 在本发明的抗体组合物一线治疗后，抗体组合物也可用于重复治疗复发性肿瘤，因为该组合物不导致抗性肿瘤的选择。 进一步的治疗用途是使用本发明的抗体组合物治疗对已知抗EGFR抗体具有抗性的癌症。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.02 秒)
